Corticotropin-releasing hormone receptor antagonists: An update

Endocrine Development

Volumn 17, Issue , 2009, Pages 36-43

  Zoumakis, E ^a   Chrousos, G P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CP 154 526; DMP 904; FLAVONOID; NBI 34041; NBI 35 965; PAROXETINE; R 278995; RETINOL; SAUVAGINE; UNCLASSIFIED DRUG; UROCORTIN I; UROCORTIN II; UROCORTIN III; UROTENSIN I;

ADD ON THERAPY; ADDICTION; ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; ANXIETY DISORDER; ARTHRITIS; ATOPIC DERMATITIS; BRAIN ISCHEMIA; CLINICAL TRIAL; COCAINE DEPENDENCE; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; HORMONE ACTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE RESPONSE; INFLAMMATORY DISEASE; IRRITABLE COLON; MAJOR DEPRESSION; NIDATION; NONHUMAN; OPIATE ADDICTION; PATHOPHYSIOLOGY; PLACENTA ACCRETA; POSTTRAUMATIC STRESS DISORDER; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PSORIASIS; RECEPTOR BLOCKING; REVIEW; SEIZURE; SEPTIC SHOCK; SLEEP DISORDER; STRESS;

BRAIN; CORTICOTROPIN-RELEASING HORMONE; HUMANS; MENTAL DISORDERS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL;

EID: 84925875556     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000262526     Document Type: Review

References (38)

1. Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and betaendorphin. Science 1981;213:1394-1397.
2. Charmandari E, Tsigos C, Chrousos G: Endocrinology of the stress response. Annu Rev Physiol 2005;67:259-284.
3. Dautzenberg FM, Hauger RL: The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002;23:71-77.
4. Grammatopoulos DK, Chrousos GP: Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 2002;13:436-444.
5. Hillhouse EW, Grammatopoulos DK: The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 2006;27:260-286.
6. Arai M, Assil IQ, Abou-Samra AB: Characterization of three corticotropin-releasing factor receptors in catfish: a novel third receptor is predominantly expressed in pituitary and urophysis. Endocrinology 2001;142:446-454.
7. Kalantaridou SN, Zoumakis E, Makrigiannakis A, Godoy H, Chrousos GP: The role of corticotropinreleasing hormone in blastocyst implantation and early fetal immunotolerance. Horm Metab Res 2007;39:474-477.
8. J Karalis K, Muglia LJ, Bae D, Hilderbrand H, Majzoub JA: CRH and the immune system. Neuroimmunology 1997;72:131-136.
9. Christos TE, Arvanitis A: Corticotrophin-releasing factor receptor antagonists. Expert Opin Ther Patents 1998;8:143-152.
10. Zorrilla EP, Koob GF: The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 2004;13:799-828.
11. Chen C: Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics. Curr Med Chem 2006;13:1261-1282.
12. Ising M, Holsboer F: CRH-sub-1 receptor antagonists for the treatment of depression and anxiety. Exp Clin Psychopharmacol 2007;15:519-528.
13. Holsboer F, Ising M: Central CRH system in depression and anxiety: evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 2008; 583:350-357.
14. Tache Y, Bonaz B: Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J Clin Invest 2007;117:33-40.
15. Bao AM, Meynen G, Swaab DF: The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 2008;57:531-553.
16. Stevens SL, Shaw TE, Dykhuizen E, Lessov NS, Hill JK, Wurst W, Stenzel-Poore MP: Reduced cerebral injury in CRH-R1 deficient mice after focal ischemia: a potential link to microglia and atrocytes that express CRH-R1. J Cereb Blood Flow Metab 2003;23:1151-1159.
17. Shaham Y, Erb S, Leung S, Buczek Y, Stewart J: CP-154,526, a selective, nonpeptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 1998;137:184-190.
18. Stinus L, Cador M, Zorrilla EP, Koob GF: Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 2005;30:90-98.
19. Sommer WH, Saavedra JM: Targeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders. J Mol Med 2008;86:723-728.
20. Goeders NE: Stress and cocaine addiction. Pharmacol Exp Ther 2002;301:785-789.
21. Gravanis A, Margioris AN: The corticotropinreleasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem 2005;12:1503-1512.
22. Chesnokova V, Melmed S: Minireview: neuroimmuno- endocrine modulation of the hypothalamic- pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 2002;143:1571-1574.
23. Webster EL, Torpy DJ, Elenkov IJ, Chrousos GP: Corticotropin-releasing hormone and inflammation. Ann NY Acad Sci 1998;840:21-32.
24. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP: Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991;254:421-423.
25. Venihaki M, Dikkes P, Carrigan A, Karalis KP: Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J Clin Invest 2001; 108:1159-1166.
26. Chikanza IC, Petrou P, Chrousos G: Perturbations of arginine vasopressin secretion during inflammatory stress: pathophysiologic implications. Ann NY Acad Sci 2000;917:825-834.
27. Webster EL, Torpy DJ, Elenkov IJ, Chrousos GP: Corticotropin-releasing hormone and inflammation. Ann NY Acad Sci 1998;840:21-32.
28. Kempuraj D, Papadopoulou N, Stanford EJ, Christodoulou S, Madhappan B, Sant GR, Solage K, Adams T, Theoharides TC: Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. Am J Reprod Immunol 2004;52:267-275.
29. Heesen C, Gold SM, Huitinga I, Reul JM: Stress and hypothalamic- pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis. Psychoneuroendocrinology 2007; 32:604-618.
30. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, Chrousos G: Corticotropin- releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403-413.
31. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC: Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav Immun 1999;13:225-239.
32. Chrousos GP, Torpy DJ, Gold PW: Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 1998;129:229-240.
33. Vitoratos N, Papatheodorou DC, Kalantaridou SN, Mastorakos G: Reproductive corticotropin-releasing hormone. Ann NY Acad Sci 2006;1092:310-318.
34. Makrigiannakis A, Margioris AN, Le Goascogne C, Zoumakis E, Nikas G, Stournaras C, Psychoyos A, Gravanis A: Corticotropin-releasing hormone (CRH) is expressed at the implantation sites of early pregnant rat uterus. Life Sci 1995;57:1869-1875.
35. Kalantaridou SN, Zoumakis E, Weil S, Lavasidis LG, Chrousos GP, Makrigiannakis A: Reproductive corticotropin releasing hormone, implantation, and fetal immunotolerance. Crit Rev Clin Lab Sci 2007; 44:461-481.
36. Makrigiannakis A, Zoumakis E, Kalantaridou S, Coutifaris C, Margioris AN, Coukos G, Rice KC, Gravanis A, Chrousos GP: Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol 2001;2:1018-1024.
37. Bamberger AM, Minas V, Kalantaridou SN, Radde J, Sadeghian H, Loning T, Charalampopoulos I, Brummer J, Wagener C, Bamberger CM, Schulte HM, Chrousos GP, Makrigiannakis A: Corticotropinreleasing hormone modulates human trophoblast invasion through carcinoembryonic antigen-related cell adhesion molecule-1 regulation. Am J Pathol 2006;168:141-150.
38. McLean M, Bisits A, Davies J, Woods R, Lowry P, Smith R: A placental clock controlling the length of human pregnancy. Nat Med 1995;1:460-463.